Schistosomes are parasitic flatworms that cause schistosomiasis, a neglected tropical disease that affects hundreds of millions worldwide. Treatment and control of schistosomiasis relies almost entirely on the single drug praziquantel (PZQ), making the prospect of emerging drug resistance particularly worrisome. This review will survey reports of PZQ (and other drug) resistance in schistosomes and other platyhelminths, and explore mechanisms by which drug resistance might develop. Newer genomic and post-genomic strategies that offer the promise of better understanding of how drug resistance might arise in these organisms will be discussed. These approaches could also lead to insights into the mode of action of these drugs and potentially provide markers for monitoring the emergence of resistance.
INTRODUCTION
Parasitic flatworms of the genus Schistosoma cause schistosomiasis, a neglected tropical disease that affects hundreds of millions of people worldwide (van der Werf et al. 2003; King, 2010) . Schistosome infections can result in permanent damage to various organs, major morbidity, devastating effects on childhood development and adult productivity and, in some cases, death. The global health burden of schistosomiasis is now considered, in some analyses, to be similar to that of malaria or tuberculosis (Hotez and Fenwick, 2009; King, 2010) .
Although there is no vaccine, the disease can be treated and controlled with praziquantel (PZQ), a drug developed in the 1970s (Gonnert and Andrews, 1977) and shortly thereafter identified as the treatment of choice by the World Health Organization (Andrews et al. 1983) . Though new lead antischistosomal compounds have been identified (Sayed et al. 2008) , no new drugs [other than repositioned antimalarials such as artemisinins (Keiser and Utzinger, 2012) ] have entered the market since the development of PZQ. Furthermore, due to the success of PZQ, other antischistosomal drugs are no longer available in most parts of the world. Thus, treatment and control of this hugely prevalent disease relies almost entirely on a single drug.
Why has PZQ supplanted other, older drugs that have been used in the past? Probably the most important advantage of PZQ is that it is effective against all human schistosome species, while oxamniquine (which is still in limited use against Schistosoma mansoni infections) and the related drug hycanthone are not (reviewed by Cioli et al. 1995) . PZQ also has relatively mild side effects, is inexpensive, and has proven its value in large-scale schistosomiasis control efforts in a variety of countries (Vennervald et al. 2005; Xianyi et al. 2005; Toure et al. 2008) .
Reliance on a single drug for any disease of this magnitude is dangerous, as there are few if any alternatives should resistance arise. Moreover, PZQ has limitations which make this situation particularly precarious. Thus, even though PZQ has overall proved successful in treatment and control programmes, reported failure rates in the field nonetheless may reach as high as 30% (Behbehani and Savioli, 1998; Day and Botros, 2006; Mutapi et al. 2011) , and this value could be optimistic, as the standardly-used Kato-Katz technique for measuring egg counts can underestimate levels of infection and has problems with reliability (Kongs et al. 2008; Lin et al. 2008) . Additionally, liver-stage juvenile schistosomes (~28 days post infection) are refractory to PZQ, a major concern in regions with high reinfection rates. Worms become fully susceptible only when egg production begins approximately 6 weeks following infection of the mammalian host (Xiao et al. 1985; Sabah et al. 1986; Pica-Mattoccia and Cioli, 2004; Aragon et al. 2009 ). Furthermore, the molecular target of PZQ has not been rigorously defined. Thus, though substantial evidence suggests that PZQ interacts with schistosome voltage-gated Ca 2+ channels, other molecular targets have also been proposed (Redman et al. 1996; Greenberg, 2005; Doenhoff et al. 2008) . Even if the molecular target of PZQ were known however, it is clear that other downstream factors contribute to PZQ action. For example, the juvenile worms that are refractory to PZQ still undergo a Ca 2+ -dependent contraction and paralysis similar to that observed in adult worms (Pica-Mattoccia et al. 2008) . Unlike adults, however, juveniles recover and survive, indicating that though the initial target is likely similar, adaptive responses that allow parasite survival come into play in the immature, but not mature, worms (Hines-Kay et al.
2012).
Finally, though there is as of yet no indication of widespread drug resistance, researchers have identified field and laboratory isolates that exhibit significantly reduced susceptibility to PZQ (Day and Botros, 2006; Doenhoff and Pica-Mattoccia, 2006; Melman et al. 2009; Couto et al. 2011) , perhaps a forerunner for emergence of more widespread drug resistance.
Several excellent reviews that survey and discuss evidence for PZQ and other drug resistance in schistosomes have been published over the past few years (Cioli, 2000; Day and Botros, 2006; Doenhoff et al. 2008 Doenhoff et al. , 2009a Wang et al. 2012b ). As such, this review will only briefly summarize that work, and will concentrate more on new approaches for understanding potential mechanisms underlying drug resistance in schistosomes, including recent work on the possible role of multidrug transporters in drug resistance and drug action.
DRUG RESISTANCE IN SCHISTOSOMES
In any discussion of drug resistance in schistosomes, it is necessary to define clearly what drug resistance is and to distinguish it from other explanations of sub-optimal drug activity (see discussion in Day and Botros, 2006) . As opposed to tolerance, which represents an innate lack of susceptibility that is not in response to prior drug exposure, resistance is a heritable increase in the frequency of individuals in a population able to tolerate doses of a compound following exposure of that population to the drug (Prichard et al. 1980; Coles and Kinoti, 1997) . Drug resistance therefore depends on the selective pressure of drug exposure, and is heritable. Thus, to distinguish properly between resistance and native tolerance, there needs to be some knowledge of the endogenous susceptibility of a particular population prior to drug administration; typically, such information is not available for schistosomiasis treatment programmes. Indeed, historically, it has been unusual to find any regular monitoring of susceptibility for these programmes. To complicate matters further, as noted above, there is already a significant background failure rate for a drug such as PZQ, as well as a range of factors other than resistance that can increase the incidence of drug failure (e.g. compromised health and immunocompetency of the host), as enumerated in Day and Botros (2006) . One of the factors suggested to account for persistence of infections following PZQ treatment is the reduced susceptibility of juvenile parasites to the drug . Recent infections will contain a significant portion of PZQ-refractory juvenile worms, leading to less than optimal cure rates, and population genetic evidence from Brazil supports this idea. Thus, worms that persist following PZQ treatment were shown to have genotypes that do not differ significantly from susceptible worms, and therefore do not appear to represent a sub-population selected for PZQ resistance (Blanton et al. 2011) . Despite these caveats, there are nonetheless several reports of possible PZQ resistance in schistosomes, both in the laboratory and in the field (reviewed by Fallon et al. 1996; Cioli, 2000; Day and Botros, 2006; Doenhoff et al. 2008; Wang et al. 2012b ), including those using newer strategies for experimentally inducing and screening for PZQresistant schistosomes. Fallon and Doenhoff (1994) exploited an approach similar to that used to induce oxamniquine/ hycanthone resistance in the laboratory (Cioli et al. 1993) to select for resistance to PZQ in S. mansoni. Thus, sub-curative, but increasing PZQ doses were administered to S. mansoni-infected mice over seven passages through the life cycle (a separate group of worms was also selected for resistance to oxamniquine in this study). By the seventh life cycle passage, this PZQ drug pressure produced a population of schistosomes in which 93% of the worms survived a PZQ dose that killed 89% of control, unselected worms. Interestingly, PZQ-and oxamniquine-resistant worms showed no crossresistance to the other drug, indicating that resistance to the two drugs arises via different mechanisms. More recently, experimentally-induced PZQ resistance has been reported in Schistosoma japonicum using a similar approach (Liang et al. 2011) .
EXPERIMENTALLY-INDUCED PZQ RESISTANCE
A notable recent advance in obtaining PZQ-resistant schistosomes uses drug selection on the asexual stages of the life cycle in the snail host (Couto et al. 2011) . The technique derives from observations showing that treating S. mansoni-infected Biomphalaria glabrata snails with 1000 mg/kg PZQ interrupts almost 90% of cercarial shedding (Mattos et al. 2007 ). Based on that finding, Couto et al. (2011) used successive treatments of B. glabrata infected with S. mansoni (LE strain) with the far lower dose of 100 mg/kg PZQ to select for cercariae that, upon infection of mice, developed into adult worms with a significantly reduced susceptibility to PZQ. The ED50 of PZQ for these LE-PZQ worms in mice was approximately five-fold higher than that for the parental LE strain (362 mg/kg for LE-PZQ vs 68 mg/kg for LE). Following PZQ, LE-PZQ worms were also less contracted than LE worms and, as assayed by fluorescent probes, showed less severe tegumental damage and, unlike LE worms, appeared to retain a functional excretory system (Couto et al. 2010 ). The ability to use this approach to select for drug resistance at the snail stage is far less costly and labour intensive than previous strategies of applying drug pressure through multiple intramammalian-stage passages. It holds the promise of much more readily providing new drug-resistant isolates that will be useful for studying the mechanisms of PZQ resistance and perhaps lend insights into the mode of action of PZQ.
FIELD ISOLATES
There have been several reports of schistosome field isolates exhibiting reduced PZQ susceptibility. Many of these reports have been thoroughly reviewed and discussed by others, and will therefore be described only briefly here. More recent reports will also be included.
In Northern Senegal, lower than expected cure rates were initially reported in the 1990s for S. mansoni infections treated with PZQ. Alarmingly, cure rates were reported to be as low as 18% (Gryseels et al. 1994; Stelma et al. 1995) . Subsequent follow-up studies and analysis of the data (Fallon, 1998; Gryseels et al. 2001; Danso-Appiah and De Vlas, 2002) suggested that some portion (though not all) of this drug failure could be attributed to factors other than drug resistance, including high-intensity infection, rapid reinfection and transmission, presence of PZQ-refractory juvenile worms, variations in methodology for analysis of efficacy, and perhaps native tolerance of these schistosomes. Interestingly, in patients relocated to urban areas (which do not have ongoing transmission), cure rates rose to nearnormal levels (Gryseels et al. 2001 ). Furthermore, despite the reduced cure rates in the area of interest, PZQ treatment nonetheless dramatically lowered the infection intensity and curbed morbidity in treated individuals (reviewed by Fallon, 1998) . On the other hand, worms from the Senegalese isolate exhibiting reduced cure rates are also less susceptible to PZQ when grown in experimentally-infected mice (Fallon, 1995; Fallon et al. 1997 ), suggesting loss of PZQ sensitivity is an endogenous trait of the worms themselves. Furthermore, in both human and mouse infections, these worms were susceptible to oxamniquine, which, like PZQ, is not effective against immature worms, casting some doubt on arguments suggesting low cure rates in this area may reflect large numbers of PZQrefractory juvenile worms due to high rates of transmission (Fallon et al. 1997; Stelma et al. 1997) .
Another site for intense study of potential PZQ resistance has been in Egypt, where schistosomes were isolated from several S. mansoni-infected patients (1·6% of those screened) who continued to pass viable eggs following three successive doses of PZQ . The schistosomes isolated from these patients were subsequently propagated in mice, where they showed 3-5-fold lower sensitivity to PZQ, as measured by ED50 (Ismail et al. , 1999 . Tests of known responses of worms to PZQ in vitro (i.e. in the absence of any confounding host factors) showed that at least some of these isolates were less susceptible to the drug (Ismail et al. 1999; William et al. 2001a) . Indeed, in vitro measures of PZQ susceptibility correlated well in some cases with ED50 determinations in murine infections (William and Botros, 2004) , further indicating that factors in the worms themselves were responsible for the reduced PZQ susceptibility of these isolates. Interestingly, approximately half of the isolates tested retained their lower response to PZQ even after multiple passages through the life cycle in the absence of drug pressure, while others reverted. Indeed, application of drug pressure does not appear to be required for maintenance of the PZQ insusceptibility trait (Sabra and Botros, 2008) , and ED50 differences, though reproducible, are relatively small (2-3-fold), and certainly not indicative of 'super-resistant' worms (Cioli and Pica-Mattoccia, 2005) . On the other hand, those isolates that did retain the trait often exhibited evidence of compromised biological fitness such as reduced cercarial production by infected snails (William et al. 2001b ). This observation, as well as those of others suggest that there are costs to schistosomes associated with lessening PZQ susceptibility. These costs may serve to limit the spread of PZQ resistance. Indeed, 10 years after the initial Egyptian studies, the same villages in Egypt in which the original PZQ failures were followed up and revealed no evidence of uncured patients despite a decade of drug pressure (Botros et al. 2005) . The presence of large refugia in endemic areas may also limit the spread of resistance; indeed, PZQ-refractory immature schistosomes may act as a refugia ).
Further evidence for isolates showing PZQ insusceptibility has been found in Kenya. Researchers used an in vitro assay on miracidia hatched from eggs excreted by S. mansoniinfected Kenyan car washers to screen for S. mansoni exhibiting decreased susceptibility to PZQ ). Different patients produced eggs that hatched into miracidia with variable PZQ sensitivity (as measured by miracidial killing); miracidia from previouslytreated patients showed significantly lower sensitivity to the drug. Further characterization of an isolate from a patient who was never fully cured by PZQ (KCW) revealed that adult worms derived from these eggs were less sensitive to PZQ, both in vivo, in murine infections and in vitro, as assayed by schistosome length. Interestingly, the reduced susceptibility of one sub-isolate of KCW was heritable and persisted through at least 6 life cycle passages in the absence of drug pressure. However, a second KCW sub-isolate had reverted to a PZQ-susceptible state when retested after 8 generations. This now-susceptible sub-isolate survived; the sub-isolate that retained PZQ tolerance eventually perished ). Thus, as with the Egyptian isolates, there appears to be variability in the stability of this trait, as well as a biological cost associated with PZQ insusceptibility.
There have also been attempts to assess the status of PZQ resistance in other species of schistosomes that infect humans (S. japonicum, S. haematobium). China has for many years relied on PZQ-based chemotherapy in its programme against S. japonicum infections. Wang et al. (2012b) recently reviewed several studies that monitored different endemic areas of China for evidence of PZQ insusceptibility. These studies found little if any evidence for emerging PZQ resistance, and suggest that, despite decades of intense chemotherapy, PZQ continues to be effective in treating schistosomiasis japonicum in China (Yu et al. 2001; Wang et al. 2010 Wang et al. , 2012a Seto et al. 2011) . Isolated incidents of failure of PZQ to cure S. haematobium infections have been reported, including a notable case in which PZQ failed to cure Brazilian soldiers returning from Africa (Silva et al. 2005) , though there is currently no evidence for heritable resistance (Herwaldt et al. 1995; Alonso et al. 2006) .
Evidence for drug failure has also been found in other trematodes. Of particular interest is the liver fluke Fasciola hepatica. Though not particularly susceptible to PZQ, F. hepatica can be treated quite effectively with other compounds such as the benzimidazoles, which target -tubulin, and are most frequently used as anti-nematodals. The benzimidazole triclabendazole (TCBZ) is effective against both immature and mature flukes (Boray et al. 1983 ) and has seen widespread use since its introduction. Recent reports have suggested the localized emergence of TCBZ-resistant fluke isolates (Moll et al. 2000; Fairweather, 2011) , and work described below has focused on defining the underlying source of resistance in one of these TCBZ-resistant isolates.
MECHANISMS OF RESISTANCE
Resistance to a single class of drugs can arise via several mechanisms. The most obvious is target modification. For example, benzimidazoles such as albendazole act to inhibit microtubule polymerization; in nematodes and fungi, resistance has been mapped to a F200Y point mutation in -tubulin (Kwa et al. 1995) . Similarly, simultaneous point mutations in three glutamate-gated chloride channel -type subunits in Caenorhabditis elegans confer resistance (~4000-fold) to the antiparasitic drug ivermectin (IVM) in these worms (Dent et al. 2000) . Interestingly, mutations in the Dyf (dye filling defective) class of genes, which appear to affect cuticle permeability, produce moderate IVM resistance (2-5fold) and act additively to increase resistance of the channel mutations. This effect speaks to yet another mechanism for generation of resistance, namely heritable alterations that reduce drug availability or activity. These changes can be in uptake/ permeability, activation/ metabolism or drug effux.
One of the more instructive cases of such non-target-dependent development of resistance comes from studies on schistosome resistance to oxamniquine (reviewed by Cioli et al. 1995) . As noted above, oxaminiquine is highly effective against S. mansoni, but lacks activity against other human schistosomes such as S. haematobium and S. japonicum (hycanthone, a related antischistosomal compound, is active against S. mansoni and S. haematobium, but not S. japonicum). In a series of elegant and challenging experiments using genetic crosses of drug-sensitive and drug-resistant schistosomes, Donato Cioli and colleagues showed that oxamniquine/hycanthone resistance in these worms was controlled by a single autosomal recessive gene. They also showed that the antischistosomal activity of the drug requires biotransformation to an active form by a parasite sulfotransferase. When activated, the drug is thought to act as an alkylating agent of schistosome DNA and other macromolecules, interfering with nucleic acid synthesis (Cioli and Pica-Mattoccia, 1984; Cioli et al. 1992 Cioli et al. , 1993 . The drug is inactive against schistosome species that lack this sulfotransferase activity and drug resistance can arise when this activity is lost in species that normally express it ). More recent similar genetic studies on worms showing reduced sensitivity to PZQ suggest either dominant (Liang et al. 2003) With regard to PZQ failure, the fact that the PZQ target has not been rigorously defined makes the search for differences more problematic. However, no clear changes in candidate targets have been found to date. Thus, voltage-gated Ca 2+ (Ca v ) channel subunits have been implicated in PZQ action (Greenberg, 2005; Nogi et al. 2009 ), but an examination of Ca v channel subunits in different isolates showing reduced PZQ susceptibility revealed no meaningful sequence differences or changes in expression levels (Valle et al. 2003; Kohn and Greenberg, unpublished data) . On the other hand, reducing Ca v channel subunit levels in the planarian Dugesia japonica confers resistance to these free-living platyhelminths against PZQ-elicited dramatic disruptions of normal regeneration patterns (Nogi et al. 2009; Zhang et al. 2011) . The relationship between PZQ effects on planarian regeneration vs. its antischistosomal activity is not clear. Interestingly, however, pre-treating worms with the actin depolymerizing agent cytochalasin D renders S. mansoni refractory to PZQ, suggesting that changes in cytoskeletal dynamics can alter susceptibility to PZQ (Pica-Mattoccia et al.
2007).
There are also several non-target-based changes that could alter PZQ effectiveness. For example, as noted above, juvenile schistosomes are refractory to PZQ. Additionally, adult female schistosomes, though still PZQ-sensitive, are more tolerant of the drug than adult males (Pica-Mattoccia and Cioli, 2004) . Thus, changes in worm maturation rates (Fallon et al. 1997) or sex ratios could influence the effectiveness of PZQ. Since PZQ-induced killing of S. mansoni within the mammalian host appears to be immune dependent (Brindley and Sher, 1987; Doenhoff et al. 1987; Brindley, 1994) , another possibility is that loss or modulation of schistosome antigens that become exposed following PZQ treatment could lead to reduced antischistosomal activity. Interestingly, recent evidence indicates that two other platyhelminths (the trematode Dicrocoelium dendriticum and the cestode Hymenolepis nana) are not capable of enzymatically metabolizing PZQ (Vokřál et al. 2012) .
Acknowledging the caveat that schistosomes may differ from these other platyhelminths, these results nonetheless suggest that development of more efficient PZQ metabolism by the parasite is not a particularly likely scenario for acquisition of PZQ resistance.
Molecular differences associated with reduced PZQ susceptibility in schistosomes would provide useful markers to monitor emergence of resistance in drug administration programmes. They could also serve as entrées into understanding how resistance develops and provide insights into the mechanism of drug action. There have been a handful of attempts to define such molecular correlates of PZQ resistance. For example, subtractive PCR and cloning of differentially-expressed RNAs revealed higher levels of an RNA encoding subunit 1 of mitochondrial cytochrome c-oxidase (SCOX1) in schistosomes selected for reduced PZQ susceptibility (Pereira et al. 1998) . Analysis by semi-quantitative RT-PCR confirmed that the SCOX1 RNA was expressed at 5-10-fold higher levels in the resistant worms than in a PZQ-sensitive strain. Interestingly, no differences were found in expression of RNAs encoding SMDR2, a schistosome multidrug transporter (see below), nor NADH dehydrogenase subunit 5, another mitochondrial gene. Surprisingly, however, the enzymatic activity of cytochrome c-oxidase showed an expression pattern opposite to that found for the SCOX1 RNA. Thus, cytochrome c-oxidase activity in resistant worms was approximately 4-fold lower than in the PZQ-susceptible worms, an unexpected result given the 5-10-fold higher levels of SCOX1 RNA found in the resistant worms.
Another group (Tsai et al. 2000) used random amplified polymorphic DNA (RAPD) PCR to test for markers of PZQ resistance. They found that an Egyptian isolate with reduced PZQ susceptibility (SO5) had 2 major differences in banding pattern from several PZQ-sensitive strains from the same endemic area of Egypt. Whether this difference can serve as a marker is unclear, as are any potential functional implications.
One of the more common mechanisms for development of drug resistance is through increased drug effux, often mediated by multidrug transporters. Multidrug transporters underlie multidrug resistance (MDR), a phenomenon in which resistance to a single drug is accompanied by unexpected cross-resistance to several structurally unrelated compounds. Multidrug transporters have broad substrate specificity and actively remove xenobiotics and toxic compounds, including drugs, from cells and tissues, though non-transport-related MDR can also occur (Pommier et al. 1999 (Pommier et al. , 2004 . Genes for multidrug transporters are found in all living cells (Blackmore et al. 2001) , and are classified into five basic families (Paulsen, 2003; Higgins, 2007) . The crystal structure of at least one representative of each of these families has been solved (van Veen, 2010). Broadly speaking, these different transporter types fit into one of two major classes, the primary-active transporters and the secondary-active transporters (Ventner et al. 2005) . The primary-active transporters couple translocation of substrate directly to the hydrolysis of ATP, while transport in the secondaryactive transporters utilizes chemiosmotic energy derived from the electrochemical gradient of proton/sodium ions across the cytoplasmic membrane.
Members of the ATP-binding cassette (ABC) superfamily of transporters are primary-active transporters that comprise one of the largest groups of transmembrane proteins found in living cells (Dassa and Bouige, 2001; Borst and Elferink, 2002) . ABC transporters are found in organisms from all living kingdoms. They bind and hydrolyze ATP and use the resultant energy to translocate compounds across the membrane. ABC importers transport compounds into the cell, and are found in prokaryotes; ABC exporters are effux transporters found in both prokaryotes and eukaryotes (Dassa and Bouige, 2001; Saier and Paulsen, 2001) .
All ABC transporters share at least one highly conserved ATPase domain containing the Walker A and Walker B motifs typically found in ATPases as well as a specific signature motif. Full ABC transporters contain two of these cytoplasmic ATP-binding cassettes that alternate with two membrane-spanning domains; half transporters contain one of each of these structural features (Ambudkar et al. 2003; Szakacs et al. 2006) . Vertebrates have on the order of 50 ABC transporter genes that define seven distinct sub-families (designated ABCA to ABCG) based on phylogenetic analysis (Dean et al. 2001; Dean and Annilo, 2005) . Subsets of these ABC transporters are associated with MDR (Szakacs et al. 2006 ). The S. mansoni genome appears to contain approximately 25 genes for ABC transporters, including several potentially involved in MDR (Kasinathan and Greenberg, 2012) .
Largely because of its role in MDR in cancer chemotherapy, P-glycoprotein (Pgp; ABCB1) is the most thoroughly studied of the eukaryotic multidrug transporters, and mammalian and C. elegans Pgp have recently been crystallized and their structures solved (Aller et al. 2009; Jin et al. 2012) . MDR is linked to gene amplification, overexpression or mutation of Pgp or other multidrug transporters, resulting in increased drug effux (reviewed by Borst and Elferink, 2002; Ambudkar et al. 2003; Szakacs et al. 2006 ). In addition to Pgp, known ABC proteins involved in MDR include the multidrug resistance-associated proteins (MRPs; ABCCs), breast cancer resistance protein (BCRP; ABCG2), as well as others (Szakacs et al. 2006 ).
Pgp and other multidrug transporters such as MRP1 transport a broad spectrum of compounds including several anticancer and other drugs (Kartner et al. 1983; Higgins, 2007) . Though the substrate specificities of the transporters show some overlap, there are clear preferences. Thus, Pgp shows selectivity for neutral and cationic hydrophobic compounds, while MRP1 preferentially transports organic anions, drugs and other compounds such as glutathione and other biotransformed conjugates, and signaling molecules such as the immunomodulator leukotriene C4 (reviewed by Ambudkar et al. 2003; Gimenez-Bonafe et al. 2008) . Members of the ABC transporter family also show selectivity for biologically significant compounds such as lipids, steroids, cyclic nucleotides and peptides, indicative of their important roles in cellular and organismal physiology (Mizutani et al. 2008; van de Ven et al. 2009 ). In addition to the broad selection of substrates that interact with these transporters, there are also a host of inhibitors that can reverse MDR by blocking multidrug transporter-mediated drug effux (reviewed by Gimenez-Bonafe et al. 2008) . Many of these inhibitors are inexpensive and safe compounds in wide clinical use (e.g. verapamil). Indeed, PZQ is an inhibitor of both mammalian and S. mansoni Pgp (Hayeshi et al. 2006; Kasinathan et al. 2010a ).
MULTIDRUG TRANSPORTERS IN SCHISTOSOMES AND OTHER TREMATODES
Could changes in multidrug transporter expression or structure be contributing to drug resistance in schistosomes? There are precedents in the literature for such an association, as ABC multidrug transporters such as Pgp have been implicated in drug resistance in other parasites, including parasitic helminths (reviewed by Kerboeuf et al. 2003; Jones and George, 2005; James et al. 2009; Leprohon et al. 2011; Lespine et al. 2012) . For example, the macrocyclic lactone ivermectin is an anthelmintic that is both a substrate and inhibitor of Pgp. Indeed, the excellent safety profile of ivermectin is due in large part to Pgp in the blood-brain barrier excluding the drug from the host central nervous system; defects in Pgp in the blood-brain barrier result in hypersensitivity to ivermectin neurotoxicity (Schinkel et al. 1994; Mealey et al. 2001) . Ivermectin also likely interacts with nematode multidrug transporters, and resistance to it and other macrocyclic lactones is associated with changes in Pgp alleles or expression levels. Notably, several studies show that co-administration of MDR reversing agents (e.g. Pgp inhibitors such as verapamil) can increase the efficacy of macrocyclic lactones in drug-resistant and -sensitive nematodes (Xu et al. 1998; Molento and Prichard, 1999; Bartley et al. 2009; Tompkins et al. 2011; Ardelli and Prichard, 2013) .
There have also been reports suggesting a role for ABC multidrug transporters in other platyhelminths. As noted above, certain F. hepatica isolates exhibit reduced susceptibility to TCBZ. Recent preliminary evidence indicates that an amino acid substitution in a critical region of F. hepatica Pgp is associated with TCBZ resistance (Wilkinson et al. 2012) . Work on another liver fluke, F. gigantica, provided evidence for expression of four ABC multidrug transporters in this worm, with expression of two of them increased in the presence of TCBZ in isolated fluke cells. Furthermore, effux of rhodamine from these fluke cells could be inhibited by a MDR reversing agent (Kumkate et al. 2008) .
Work on schistosome Pgp and other multidrug transporters essentially began in 1994, when cDNAs encoding Pgp (SMDR2) and an ABC half transporter (SMDR1) were cloned and sequenced (Bosch et al. 1994) . Two different oxamniquine/hycanthone-resistant isolates showed no evidence for amplification or overexpression of SMDR2. As noted above, the subsequent availability of the sequenced genome revealed ~25 ABC transporter-like sequences in S. mansoni, including other Pgp-like genes and representatives of other ABC transporter sub-families (Kasinathan and Greenberg, 2012) .
Fluorescent substrates of mammalian Pgp and MRP have been used to localize these substrates to the excretory system of schistosomes (Sato et al. 2002 (Sato et al. , 2004 . PZQ dramatically disrupts the distribution of the Pgp substrate in PZQ-susceptible worms Oliveira et al. 2006) , but not in the recently-derived S. mansoni isolate selected at the snail stage for reduced PZQ susceptibility (Couto et al. 2010) . These results suggest a role for ABC multidrug transporters in schistosome excretory activity, and may be providing hints of a role for Pgp and other ABC transporters in PZQ resistance.
There are further indications that multidrug transporters may be involved in modulating levels of PZQ susceptibility in schistosomes. PZQ is both an inhibitor and a substrate of recombinant SMDR2 (Kasinathan et al. 2010a) , and chronic exposure of worms to sublethal concentrations of PZQ results in up-regulation of SMDR2 and schistosome MRP1 (SmMRP1), and changes the distribution of anti-Pgp immunoreactivity in the worm (Messerli et al. 2009; Kasinathan et al. 2010b ). Importantly, higher levels of schistosome SMDR2 and SmMRP1 are associated with reduced PZQ susceptibility (Messerli et al. 2009; Kasinathan et al. 2010b ). Indeed, EE2, an Egyptian isolate with reduced PZQ susceptibility, expresses dramatically higher levels of SMDR2 RNA and protein (Messerli et al. 2009 ); interestingly, SmMRP1 does not appear to be expressed at a higher level in EE2 (Kasinathan et al. 2010b) . At this juncture, only an association between reduced drug susceptibility and ABC multidrug transporters has been demonstrated. Further pharmacological and genetic experiments will be required to establish a causal relationship. However, we have recently used both of these approaches to implicate S. mansoni ABC multidrug transporters in schistosome reproduction (Kasinathan et al. 2011 ).
NEW POST-GENOMIC APPROACHES TO DEFINE THE MECHANISMS OF

DRUG RESISTANCE IN SCHISTOSOMES
For a variety of reasons, most notably that they are obligate parasites, schistosomes are notoriously difficult systemsfor experimental analysis. In recent years, however, tools that are feasible in other organisms have been, or are being, adapted to schistosomes. These new approaches, some of which are listed below, hold the promise of providing major advances in our knowledge about schistosome biology and physiology, including the underlying basis for anti-schistosomal drug action and drug resistance.
GENE MAPPING
As noted, traditional genetic experiments provided important insights into the mechanism of oxamniquine/hycanthone drug resistance and mode of action (Cioli et al. 1993) . Genetic crosses showed that oxamniquine/hycanthone resistance is linked to inheritance of a single autosomal recessive gene, while reduced PZQ susceptibility appears to be either a dominant (Liang et al. 2003) or partially dominant (Pica-Mattoccia et al. 2009 ) trait. Newer, postgenomic approaches have the potential for much greater power. By combining the ability to conduct genetic crosses with the availability of a high resolution genetic linkage map (Criscione et al. 2009 ) and an increasingly well-assembled and annotated genome sequence for S. mansoni (Protasio et al. 2012) , linkage mapping holds the promise to become a feasible approach for locating genes that underlie drug resistance. A particular appeal of this approach is that it surveys all of the genome, and is therefore not based on preconceived ideas about mechanism or possible candidate genes.
TRANSCRIPTOMICS AND OTHER' -OMICS'
Examination of global changes in gene expression following drug treatment or between isolates showing differential drug susceptibility may provide an entrée into identification of genes underlying drug action or resistance. Microarray studies of schistosomes following low-dose PZQ treatment ex vivo have revealed molecular pathways that appear to be activated by PZQ, including expression of multidrug transporters and Ca 2+ regulatory-, stress-, and apoptosis-related pathways (Aragon et al. 2009; Hines-Kay et al. 2012) .
Comparison of the gene expression patterns of PZQ-refractory juvenile and PZQ-susceptible adult schistosomes following sub-lethal PZQ showed that the juvenile worms exhibited a greater transcriptomic flexibility that may allow them to respond to and survive exposure to PZQ.
Although microarray studies can be enlightening, the greater power of next-generation sequencing technologies such as RNAseq, along with robust bioinformatics algorithms (Cantacessi et al. 2012) , may provide a higher-resolution analysis of meaningful gene expression changes in schistosomes following exposure to PZQ, as well as new drug targets. Furthermore, use of these approaches on worms treated with PZQ within the host should provide a better approximation of real-world responses to treatment. Examination of differences in microRNAs, which could produce reduced drug susceptibility by repressing expression of the drug target (or associated co-factors), could provide novel pathways to development of resistance (Devaney et al. 2010 ). Other '-omics' analyses of parasite responses to drug treatment should of course be explored; proteomic, glycomic, lipidomic and metabolomic approaches will likely also prove enlightening. Powerful 'chemogenomics' and comparative genomics approaches have the potential to provide new drug targets and perhaps insights into drug resistance (Caffrey et al. 2009; Swain et al. 2011 ). Finally, in order to obtain a better understanding of mechanisms underlying resistance, these same tools should be brought to bear to compare drug-sensitive worms vs isolates with reduced susceptibility.
RNA INTERFERENCE (RNAI)
RNAi is gene silencing (or suppression) triggered by exogenous double-stranded (ds) RNA. Knockdown of genes using RNAi has proven to be an especially powerful molecular tool for analysis of a variety of gene functions. Though many parasitic nematodes appear to be refractory to RNAi Selkirk et al. 2012) , the methodology has proven relatively robust in schistosomes, and has provided important insights into schistosome biology (reviewed by Krautz-Peterson et al. 2010) . Both small interfering ds RNAs (siRNAs) and larger dsRNAs are effective. Analysis of phenotypes following knockdown of potential drug targets or of components of pathways hypothesized to modulate drug activity could provide important clues regarding drug action and mechanisms underlying resistance. However, there are several caveats for the use of this approach in schistosomes. For example, there can be tremendous variability in knockdown efficiency depending on the target (Mourao et al. 2009; Stefanic et al. 2010) . To a first approximation, targets expressed in the intestine and on the tegument appear to be most amenable to knockdown. Off-target effects, in which dsRNA directs knockdown of transcripts other than those intended, have been reported in other systems and are an ever-present concern (Sioud, 2011). Knockdown is furthermore often partial even when successful, with perhaps 30-50% of transcripts remaining; a 50% level of expression might be sufficient to maintain function and mask any detectable phenotypes. Redundancy of genes can also often be a confounding factor. For example, as noted above, there are several predicted Pgp-like genes in S. mansoni, and suppression of one might be compensated for by the others, again masking a phenotype. Defining phenotypes other than those that are obvious (death, paralysis, egg production) can be challenging, even ex vivo, and particularly in vivo, within the host. Finally, it is currently technically difficult to perform these types of experiments in vivo, within the mammalian host. As knockdown of genes in infectious cercariae has not been reported, experiments are instead typically done by performing knockdown in schistosomules produced in vitro from cercariae. These schistosomules are then injected into the host, which is a far less efficient means of infection than using cercariae. Though this approach has been successful (see, for example, Bhardwaj et al. 2011 ), there is low and variable recovery of the adults that develop from these injected schistosomules, confounding data analysis. Reports of knockdown of parasite genes by injecting the infected host with siRNA have appeared (Pereira et al. 2008; Cheng et al. 2009; Yang et al. 2012) , though it remains to be seen if this approach will be incorporated more generally in the field.
TRANSGENESIS
Although RNAi is an extraordinarily powerful tool for analyzing gene function, a more complete armamentarium for functional genomics in schistosomes will require the availability of somatic and germline transgenesis. In conjunction with the completion of draft genomes for all three major human schistosome species and many years of concerted efforts, relatively efficient gene insertion and knockout strategies may be coming to fruition for schistosomes Beckmann and Grevelding, 2012; Suttiprapa et al. 2012) . Of particular note is an exciting recent report of murine leukaemia virus-mediated germ-line transgenesis and insertional mutagenesis in S. mansoni (Rinaldi et al. 2012a) . Other technical advances have also been steadily appearing, including antibiotic selection of transgenic worms (Rinaldi et al. 2012b ) and vector-mediated RNAi Duvoisin et al. 2012 ). These types of advances offer the promise of more feasible transgenesis in schistosomes, with more widespread adoption, and hold the promise of new strategies for studies of drug action and resistance. A model for the type of power that could be brought to bear on these questions was recently provided in studies using transgenesis of C. elegans resistant to the anthelmintic emodepside. These C. elegans were transformed with genes from other nematodes or mammals to investigate the role of Ca 2+ -activated potassium (SLO-1) channels in the selectivity and mode of action of this drug (Crisford et al. 2011; Welz et al. 2011 ).
OTHER ADVANCES
One of the challenges of working with schistosomes is that they are obligate parasites and, currently, only one developmental stage (schistosomules) can be archived by freezing for reestablishment of the life cycle (Cooper et al. 1989) . Though primary S. mansoni cells such as muscle fibres have been used to study drug and neurotransmitter action (Novozhilova et al. 2010) , the establishment of cell lines in schistosomes would be a huge boon for the field, and could provide high-throughput screening opportunities to investigate drug targets and test hypotheses regarding mechanisms of resistance. To date, no such cell lines have been successfully established, but newer approaches for immortalization of cells are promising (Quack et al. 2010) , and advances in the study and culture of multipotent cells (neoblasts) from Schistosomes and other platyhelminths (Eisenhoffer et al. 2008; Brehm, 2010; Collins, et al. 2013 ) may eventually prove adaptable to schistosomes.
High-and medium-throughput systems for screening schistosome phenotypes such as paralysis or contraction will also be useful. These include video analysis systems (Caffrey et al. 2009 ) and a novel adoption of the xCelligence (Roche) system for measuring electrical impedance across micro-electrodes interdigitated on the bottom of tissue culture plates (Smout et al. 2010) . New and powerful markers that have been developed for S. mansoni organs and developmental stages (Collins et al. 2011) should also aid in these types of analyses.
CONCLUDING REMARKS
The prospect of schistosomes developing widespread resistance to PZQ is an alarming one, and understanding mechanisms by which resistance might emerge could provide markers for monitoring response to mass treatment programmes, as well as possible strategies for reversing drug resistance. It is somewhat heartening that worms exhibiting apparent PZQ resistance often appear to be compromised, and furthermore, exhibit relatively small (2-5fold) changes in drug susceptibility, as measured by ED50s. Indeed, typical treatment with PZQ uses an ED90 dose, which should be sufficient to eliminate worms showing 2-3-fold reductions in susceptibility (Cioli and Pica-Mattoccia, 2005) . Nonetheless, complacency is clearly unwarranted, as in both Egypt and Kenya (Ismail et al. 1999; Melman et al. 2009 ), isolates were derived from patients who simply were not cured by such doses. These patients continued to pass eggs (presumably carrying a PZQ-tolerant trait), suggesting that clinicallysignificant treatment failures potentially indicative of emerging resistance can occur in the field. One hopes that some of the newer technologies described in this review may lead to development of tools to deal with such resistance before disastrous consequences ensue.
